At the completion of the activity, the participant will be able to:

 
Understand the changes to federal law regarding the prescribing and dispensing of Buprenorphine and related controlled drugs which are prescribed for patients efforts to withdraw from addiction to controlled drugs .

Recognize the changes to DEA regulations with the recent elimination of DEA Data Waiver prescriber process, and the related elimination of the secondary DEA numbers previously used in ordering Buprenorphine for treatment of opioid addicted patients.

Understand the collateral consequences of civil and criminal charges brough by state or federal agencies even when the practitioner is able to salvage their professional license after the civil/criminal disposition resolution of their legal matter.

Define the new limitations on who is permitted to register with the DEA on behalf of the pharmacy as the pharmacy’s “Registrant”.

Describe recent examples of civil penalties for routine violations of the Controlled Substance Act found by DEA Diversion Investigators upon inspections of pharmacies